The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
Dashboard: Filter Bricks
Main page content
This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.
This guide addresses specific treatment needs of adult men living with substance use disorders. It reviews gender-specific research and best practices, such as common patterns of substance use among men and specific treatment issues and strategies.
This manual provides clinical practice guidelines for using medications in the medication-assisted treatment of alcohol use disorder. It offers guidance on prescribing acamprosate, disulfiram, oral naltrexone, and extended-release injectable naltrexone. The manual also discusses patient management. Access the literature review.
This guide helps substance use counselors treat clients with symptoms of depression and substance use conditions. Program administrators will learn how to integrate depression treatment into early drug treatment. The guidelines cover screening, assessment, treatment, counseling, cultural competence, and continuing care.
This manual offers practice guidelines and recommendations for integrating employment services into substance use disorder treatment. It also provides information about funding, policy, and legal issues.
This guide equips clinicians with information for treating chronic pain in adults living with a history of substance use. The guide discusses chronic pain management, including treatment with opioids. It also includes information about substance use assessments and referrals. Access the literature review.